Back to Report Store Home

Frontier Pharma: Orphan and Rare Dermatological Diseases – First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

  • Published: Sep-2018
  • Report Code: GBIHC483MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Orphan and Rare Dermatological Diseases, US, Innovation Trends in Products Approvals, 1987–2014

Figure 2: Orphan and Rare Dermatological Diseases, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013

Figure 3: Orphan and Rare Dermatological Diseases Global, Market by Molecule Type and Molecular Target Class, 2018

Figure 4: Orphan and Rare Dermatological Diseases, Global, Overall Pharmaceutical Pipeline by Therapy Area, 2018

Figure 5: Orphan and Rare Dermatological Diseases, Global, Overall Pipeline by Stage of Development and Molecule Type, 2018

Figure 6: Orphan and Rare Dermatological Diseases, Global, Pipeline for Key Indications by Stage of Development, 2018

Figure 7: Orphan and Rare Dermatological Diseases, Global, Pipeline for Key Indications by Molecule Type, 2018

Figure 8: Orphan and Rare Dermatological Diseases, Global, Overall Pipeline by Molecular Target and Stage of Development, 2018

Figure 9: Orphan and Rare Dermatological Diseases, Global, Pipeline for Key Indications by Molecular Target Class, 2018

Figure 10: Orphan and Rare Dermatological Diseases, Global, Pipeline and Marketed Programs by Molecular Target Class, 2018

Figure 11: Orphan and Rare Dermatological Diseases, Global, First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class and Stage of Development, 2018

Figure 12: Orphan and Rare Dermatological Diseases, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Stage of Development and Molecular Target Class, 2018

Figure 13: Orphan and Rare Dermatological Diseases, Global, Ratio of First-in-Class Programs to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018

Figure 14: Orphan and Rare Dermatological Diseases, Global, All First-in-Class Pipeline Programs, 2018 (part 1)

Figure 15: Orphan and Rare Dermatological Diseases, Global, All First-in-Class Pipeline Programs, 2018 (part 2)

Figure 16: Orphan and Rare Dermatological Diseases, Global, All First-in-Class Pipeline Programs, 2018 (part 3)

Figure 17: Orphan and Rare Dermatological Diseases, Global, All First-in-Class Pipeline Programs, 2018 (part 4)

Figure 18: Orphan and Rare Dermatological Diseases, Global, All First-in-Class Pipeline Programs, 2018 (part 5)

Figure 19: Orphan and Rare Dermatological Diseases, Global, All First-in-Class Pipeline Programs, 2018 (part 6)

Figure 20: Orphan and Rare Dermatological Diseases, Global, All First-in-Class Pipeline Programs, 2018 (part 7)

Figure 21: Orphan and Rare Dermatological Diseases, Global, First-in-Class Molecular Target Matrix Assessment, 2018 (part 1)

Figure 22: Orphan and Rare Dermatological Diseases, Global, First-in-Class Molecular Target Matrix Assessment, 2018 (part 2)

Figure 23: Orphan and Rare Dermatological Diseases, Global, First-in-Class Molecular Target Matrix Assessment, 2018 (part 3)

Figure 24: Orphan Dermatological Disease, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006–2015

Figure 25: Orphan Dermatological Diseases, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006–2014

Figure 26: Orphan and Rare Dermatological Diseases, Global, Licensing Deals by Region, Value and Year, 2006–2018

Figure 27: Orphan and Rare Dermatological Diseases, Global, Number and Aggregate Deal Value of Licensing Deals for Systemic Sclerosis, Alopecia and Epidermolysis Bullosa, 2018

Figure 28: Orphan and Rare Dermatological Diseases, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018

Figure 29: Orphan and Rare Dermatological Diseases, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type, 2006–2018

Figure 30: Orphan and Rare Dermatological Diseases Global, Licensing Deals with Disclosed Deal Values, 2006–2018

Figure 31: Orphan and Rare Dermatological Diseases, Global, Co-development Deals by Region, Value and Year, 2006–2018

Figure 32: Orphan and Rare Dermatological Diseases, Global, Number and Aggregate Deal Value of Co-development Deals for Systemic Sclerosis, Alopecia and Epidermolysis Bullosa, 2018

Figure 33: Orphan Dermatological Diseases, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018

Figure 34: Orphan Dermatological Diseases, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target Class, 2006–2018

Figure 35: Orphan and Rare Dermatological Disease, Global, Co-development Deals with Disclosed Deal Values, 2006–2018

Figure 36: Orphan and Rare Dermatological Diseases, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2018 (part 1)

Figure 37: Orphan and Rare Dermatological Diseases, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2018 (part 2)

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards